Alzheimer’s disease: Plaques impair memory formation during sleep
News Oct 22, 2015
Protein deposits associated with dementia influence brain activity during sleep -
Alzheimer's patients frequently suffer from sleep disorders, mostly even before they become forgetful. Furthermore, it is known that sleep plays a very important role in memory formation. Researchers from the Technical University of Munich (TUM) have now been able to show for the first time how the pathological changes in the brain act on the information-storing processes during sleep. Using animal models, they were able to decode the exact mechanism and alleviate the impairment with medicinal agents.
The sleep slow waves, also known as slow oscillations, which our brain generates at night, have a particular role in consolidating what we have learned and in shifting memories into long-term storage. These waves are formed via a network of nerve cells in the brain's cortex, and then spread out into other parts of the brain, such as the hippocampus.
"These waves are a kind of signal through which these areas of the brain send mutual confirmation to say 'I am ready, the exchange of information can go ahead'. Therefore, there is a high degree of coherence between very distant nerve cell networks during sleep," explains Dr. Dr. Marc Aurel Busche, scientist at the Department of Psychiatry and Psychotherapy at TUM University Hospital Klinikum rechts der Isar and TUM Institute of Neuroscience. Together with Prof. Dr. Arthur Konnerth from the Institute of Neuroscience, he headed the study which was published in the journal Nature Neuroscience.
Disrupted spread of sleep waves in Alzheimer models
As the researchers discovered, this coherence process is disrupted in Alzheimer's disease. In their study, they used mouse models with which the defects in the brains of Alzheimer's patients can be simulated. The animals form the same protein deposits, known as β-amyloid plaques, which are also visible in human patients. The scientists were now able to show that these plaques directly impair the slow wave activity. "The slow oscillations do still occur, but they are no longer able to spread properly -- as a result, the signal for the information cross-check is absent in the corresponding regions of the brain," is how Marc Aurel Busche summarizes it.
The scientists also succeeded in decoding this defect at the molecular level: correct spread of the waves requires a precise balance to be maintained between the excitation and inhibition of nerve cells. In the Alzheimer models, this balance was disturbed by the protein deposits, so that inhibition was reduced.
Low doses of sleep-inducing drugs as possible therapy
Busche and his team used this knowledge to treat the defect with medication. One group of sleep-inducing drugs, the benzodiazepines, is known to boost inhibitory influences in the brain. If the scientists gave small amounts of this sleep medication to the mice (approximately one-tenth of the standard dose), the sleep slow waves were able to spread out correctly again. In subsequent behavioral experiments, they were able to demonstrate that learning performance had now improved as well.
For the researchers, of course, these results are just a first step on the way to a suitable treatment of Alzheimer's disease. "But, these findings are of great interest for two reasons: firstly, mice and humans have the same sleep oscillations in the brain -- the results are thus transferrable. Secondly, these waves can be recorded with a standard EEG monitor, so that any impairment may also be diagnosed at an early stage," concludes the scientist.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Konnerth A et al. Rescue of long-range circuit dysfunction in Alzheimer's disease models. Nature Neuroscience, Published Online October 12 2015. doi: 10.1038/nn.4137
Catalyst Can Degrade Alzheimer's-Related Amyloid Peptide Under Near-Infrared LightNews
A new, biocompatible photooxygenation catalyst that can selectively oxygenate and degrade the pathogenic aggregation of Alzheimer's disease (AD)-related amyloid-β peptide (Αβ) under near-infrared (NIR) light irradiation has been developed.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018